Search clinical trials for: ASP7317

Total 53 results

Astellas Pharma Global Development, Inc.

Completed

A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome | Acute Myeloid Leukemia (AML)

United States, Japan
Astellas Institute for Regenerative Medicine

Completed

A Follow up Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD)

Stargardt's Macular Dystrophy

United Kingdom
Astellas Institute for Regenerative Medicine

Completed

Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Patients With AMD

Age-Related Macular Degeneration

United States
Astellas Institute for Regenerative Medicine

Completed

Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Stargardt Macular Dystrophy Patients

Stargardt's Macular Dystrophy

United States
UMN Pharma Inc.

Completed

A Study to Evaluate Intramuscular ASP7374

Influenza | Vaccine

Japan
Astellas Pharma Inc
FibroGen

Completed

A Food Effect Study to Evaluate the Pharmacokinetics of ASP1517

Healthy Subjects

Japan
Astellas Pharma Inc

Completed

ASP1517 Phase 2 Clinical Trial - Double-Blind Study of ASP1517 for the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis-

Anemia in Chronic Kidney Disease Patients Not on Dialysis

Japan
Astellas Pharma Global Development, Inc.
FibroGen

Completed

A Study to Assess the Relative Bioavailability of Roxadustat Following a Single Dose of Pediatric Azo Dye-free Tablet Formulation and Pediatric Azo Dye-free Mini-tablet Formulation Compared to a Single Dose of Azo Dye-containing Tablet Formulation in Healthy Adult Subjects

Healthy Adult Subjects

Germany
Astellas Pharma Inc

Completed

ASP1517 Pharmacokinetics Study in Anemia Patients on Hemodialysis

Anemia | Hemodialysis | Renal Impairment

Japan
Astellas Pharma Global Development, Inc.

Terminated

A Study to Find a Suitable Dose of ASP8731 and Check for Medical Problems at Each Dose in Healthy Adults

Healthy Participants

United States
Astellas Pharma Global Development, Inc.

Completed

Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP1617 in Healthy Adult Non-Asian and Japanese Subjects Including Assessment of a Food Effect

Healthy Volunteers

United States
Astellas Pharma Inc
FibroGen

Completed

A Long Term Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis Chronic Kidney Disease Patients With Anemia Converted From Erythropoieses Stimulating Agent (ESA) Treatment

Hemodialysis Patients With Renal Anemia

Japan
Seldar Pharma, Inc.

Completed

A Phase 2 Pilot Study to Assess ASP7147 in Patients With Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)

Diarrhea Predominant Irritable Bowel Syndrome

United States
Astellas Pharma Global Development, Inc.

Completed

A Study of ASP0367 in People With Kidneys That do Not Work Well and in Healthy People

Renal Impairment | Healthy Volunteers

United States
Astellas Pharma Inc
FibroGen

Completed

Pharmacokinetic Study of ASP1517 With Kremezin®

Healthy Volunteers

Japan
Astellas Pharma Inc

Active, not recruiting

Post-marketing Surveillance of EVRENZO® Tablets (Roxadustat) in Patients With Renal Anemia

Renal Anemia

Japan
Astellas Pharma Global Development, Inc.

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MA-0211 in Healthy Adult Subjects Including a Food Effect Cohort

Healthy Volunteers

United States
Astellas Pharma Inc

Completed

Safety, Tolerability and Pharmacokinetic Study of ASP1517 in Healthy Non-elderly Male Volunteers

Healthy Volunteers

Japan
Astellas Pharma Global Development, Inc.

Terminated

A Study to Evaluate ASP0367 in Participants With Reduced Maximum Oxygen Uptake Due to Poor Systemic Oxygen Extraction

Reduced Maximum Oxygen Uptake Due to Poor Systemic Oxygen Extraction

United States
UMN Pharma Inc.

Completed

A Study to Assess the Safety of ASP7374 in Adult Subjects Aged 20 or Older

Influenza | Vaccine

Japan
Astellas Pharma Inc
FibroGen

Completed

A Study of Intermittent Oral Dosing of ASP1517 in ESA-untreated Chronic Kidney Disease Patients With Anemia

Chronic Kidney Disease

Japan
Astellas Pharma Inc
FibroGen

Completed

A Study of Intermittent Oral Dosing of ASP1517 in Erythropoieses Stimulating Agent (ESA)-Naive Hemodialysis Chronic Kidney Disease Patients With Anemia

ESA-naive Hemodialysis Chronic Kidney Disease Patients With Anemia

Japan
Astellas Pharma Inc
FibroGen

Completed

A Study of Intermittent Oral Dosing of ASP1517 in Peritoneal Dialysis Chronic Kidney Disease Patients With Anemia

Peritoneal Dialysis Chronic Kidney Disease Patients With Anemia

Japan
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP7713 in Healthy Non-Japanese Adult and Elderly Subjects and Healthy Japanese Adult Subjects

Healthy Volunteers

United Kingdom
Astellas Pharma Inc
FibroGen

Completed

A Drug Interaction Study to Evaluate the Pharmacokinetics of ASP1517 and Lanthanum Carbonate Hydrate

Healthy Subjects

Japan
UMN Pharma Inc.

Completed

A Study to Evaluate the Immune Response to the ASP7373 and Its Safety in Healthy Adult Volunteers

Healthy

Japan
Astellas Institute for Regenerative Medicine

Enrolling by invitation

A Safety Surveillance Study in Subjects With Macular Degenerative Disease Treated With Human Embryonic Stem Cell-derived Retinal Pigment Epithelial Cell Therapy

Macular Degenerative Disease

United Kingdom, United States
Astellas Pharma Europe B.V.
FibroGen

Completed

A Phase 1 Study of Roxadustat in Subjects With Different Degrees of Renal Function

Impaired Renal Function | Normal Renal Function

Germany, United Kingdom
University of Oxford
Astellas Pharma Inc; European Organisation for Research and Treatment of Cancer... and other collaborators

Completed

Eurosarc Trial of Linsitinib in Advanced Ewing Sarcoma (LINES)

Refractory Ewing Sarcoma | Relapsed Ewing Sarcoma

United Kingdom, Germany, Netherlands, Italy, France
Astellas Pharma Inc

Terminated

A Study to Evaluate ASP0367 in Participants With Primary Mitochondrial Myopathy (MOUNTAINSIDE)

Primary Mitochondrial Myopathy

United States
Astellas Pharma Inc

Terminated

A Study to Assess the Safety, Tolerability and Preliminary Efficacy of ASP0367 (MA-0211) in Pediatric Male Participants With Duchenne Muscular Dystrophy (DMD)

Duchenne Muscular Dystrophy (DMD)

United States
UMN Pharma Inc.

Completed

A Study to Evaluate the Immune Response to the ASP7374 and Its Safety in Healthy Adult Volunteers

Healthy | Immunogenicity of ASP7374

Japan
Astellas Pharma Global Development, Inc.

Completed

A Study to Evaluate ASP0367 in Participants With Mild/Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function

Healthy Volunteers | Hepatic Impairment

United States
Astellas Pharma Europe B.V.
FibroGen

Completed

A Study to Investigate the Exposure and Safety and Tolerability of a Single Dose of FG-4592 in Subjects With Moderately Diminished Liver Function Compared to Those With Normal Liver Function

Hepatic Insufficiency | Healthy Subjects | PK of FG-4592

Bulgaria
Astellas Pharma Global Development, Inc.

Active, not recruiting

Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen

Advanced Cancer | Advanced Malignancies

United States
Astellas Pharma Inc

Completed

A Study to Investigate the Effect of ASP1517 After Intermittent Oral Dosing in Dialysis Chronic Kidney Disease Patients With Anemia Compared With Darbepoetin as a Reference Drug

Renal Anemia Associated With Chronic Renal Failure (CRF)

Japan
Astellas Pharma Inc
FibroGen

Completed

A Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis Chronic Kidney Disease Patients With Anemia

Hemodialysis Chronic Kidney Disease Patients With Anemia

Japan
Astellas Pharma Inc
FibroGen

Completed

A Study of Intermittent Oral Dosing of ASP1517 in Non-Dialysis Chronic Kidney Disease Patients With Anemia

Chronic Kidney Disease

Japan
Astellas Pharma Global Development, Inc.

Recruiting

A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease

Chronic Kidney Disease | Renal Anemia

Romania, Spain, Belgium, Germany, Norway, Slovakia, Denmark, Czechia, Lithuania, United Kingdom
FibroGen
AstraZeneca; Astellas Pharma Inc

Terminated

Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell Transfusion Burden

Primary MDS (Very Low, Low or Intermediate IPSS-R With <5% Blasts)

United States, Australia, Belgium, Germany, Israel, Italy, Korea, Republic of, Russian Federation, Spain, United Kingdom, France, Turkey, Canada, Denmark, India, Poland
Astellas Pharma Global Development, Inc.

Completed

A Study to Learn How [14C]ASP0367 is Processed by the Body in Healthy Men

Healthy Volunteers

United States
Astellas Pharma Europe B.V.
FibroGen

Completed

A Study to Evaluate the Dose-proportionality and Effects of FG-4592 in Healthy Young and Elderly Male and Female Subjects

Healthy Subjects | PK for FG-4592

Germany
Astellas Pharma Europe B.V.
FibroGen

Completed

A Study to Evaluate the Effects of Multiple Doses of FG-4592 on the Exposure, Safety and Tolerability and Effect of Warfarin in Healthy Subjects

Healthy Subjects | Pharmacokinetics of FG-4592

Germany
FibroGen
AstraZeneca; Astellas Pharma Europe B.V.

Completed

Safety and Efficacy Study of Roxadustat (FG-4592) for the Treatment of Anemia in End-Stage Renal Disease (ESRD) Newly Initiated Dialysis Participants (Himalayas)

Anemia in Incident Dialysis Patients

Russian Federation, Bulgaria, Thailand, United States, Argentina, Chile, Colombia, Korea, Republic of, Latvia, Malaysia, Mexico, Poland, Romania, Taiwan, Ukraine
Astellas Pharma Europe B.V.
FibroGen

Completed

Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not Requiring Dialysis (ALPS)

Anemia in Chronic Kidney Disease in Non-dialysis Patients

Spain, Belarus, Bulgaria, Hungary, Poland, Romania, Russian Federation, Serbia, Ukraine, United Kingdom, Belgium, Georgia, Italy, Colombia, Dominican Republic, Estonia, Greece, Guatemala, Panama, Peru, South Africa, Turkey
UMN Pharma Inc.

Completed

Study of ASP7374, Cell-culture-derived Influenza Vaccine

Influenza | Vaccine

Japan
UMN Pharma Inc.

Completed

Phase-3 Study of ASP7374, Cell-culture-derived Influenza Vaccine

Influenza

Japan
FibroGen
AstraZeneca; Astellas Pharma Europe B.V.

Completed

A Study of Roxadustat for the Treatment of Anemia in Participants With Chronic Kidney Disease and Not Receiving Dialysis

CKD Anemia

United States, Australia, Thailand, Korea, Republic of, Malaysia, Mexico, Taiwan, New Zealand, Argentina, Chile, Colombia, Hong Kong, Peru, Philippines, Puerto Rico, Singapore
Astellas Pharma Europe B.V.
FibroGen

Completed

Roxadustat in the Treatment of Anemia in Chronic Kidney Disease (CKD) Patients, Not on Dialysis, in Comparison to Darbepoetin Alfa (Dolomites)

Anemia in Chronic Kidney Disease in Non-dialysis Patients

Austria, Belarus, Bulgaria, Croatia, Czechia, Finland, France, Georgia, Germany, Hungary, Ireland, Israel, Latvia, Montenegro, Netherlands, North Macedonia, Poland, Portugal, Romania, Russian Federation, Serbia, Slovakia, Slovenia, Spain and more
University Health Network, Toronto
Astellas Pharma Inc; Multiple Myeloma Research Consortium

Terminated

A Trial of ASP7487 (OSI-906) in Combination With Bortezomib for the Treatment of Relapsed Multiple Myeloma

Multiple Myeloma

United States, Canada

3

Subscribe